Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating reiterated by analysts at BTIG Research in a report issued on Tuesday.
A number of other equities research analysts also recently weighed in on the company. SunTrust Banks set a $430.00 price objective on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Friday, February 9th. Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $401.00 to $415.00 and gave the company an “equal weight” rating in a report on Friday, February 9th. Leerink Swann decreased their price objective on Regeneron Pharmaceuticals from $568.00 to $502.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. Robert W. Baird raised Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating in a report on Friday, February 9th. They noted that the move was a valuation call. Finally, Guggenheim set a $530.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 9th. Four analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $463.19.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) opened at $330.69 on Tuesday. Regeneron Pharmaceuticals has a 1 year low of $313.53 and a 1 year high of $543.55. The firm has a market capitalization of $35,530.00, a PE ratio of 32.04, a P/E/G ratio of 1.39 and a beta of 1.47. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.18 and a current ratio of 3.82.
In other news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $325.60, for a total value of $325,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.80% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Shell Asset Management Co. raised its position in Regeneron Pharmaceuticals by 24.1% in the 3rd quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock worth $5,565,000 after purchasing an additional 2,999 shares during the last quarter. DnB Asset Management AS bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $9,136,000. Northpointe Capital LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $2,089,000. Cubist Systematic Strategies LLC raised its position in Regeneron Pharmaceuticals by 176.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 428 shares during the last quarter. Finally, Griffin Asset Management Inc. bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $1,579,000. Hedge funds and other institutional investors own 65.89% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.